Recombinant antibody production utilizes mammalian cell lines for the generation of therapeutic antibodies. Chinese hamster ovary (CHO) cells developed as a leading platform due to their productivity in producing complex, humanized antibodies. High-yield cultivation of CHO cells is crucial for cost-effectiveness and involves meticulous optimization